Journal
BMJ-BRITISH MEDICAL JOURNAL
Volume 334, Issue 7585, Pages 120-123Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.39024.487720.68
Keywords
-
Categories
Ask authors/readers for more resources
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
